

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board of Directors (the “**Board**”) of Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Li Bin is appointed as an executive director of the Company (“**Director**”) with effect from 3 February 2026. Mr. Li Bin is also appointed as the co-chairman of the Board.

Mr. Li Bin (李斌先生) (“**Mr. Li**”), aged 52, has over 20 years of experience in enterprise and business management. Mr. Li is the founder and the chairman of Shanghai Anbaida Investment Management Consulting Co., Ltd. (上海安百達投資管理顧問有限公司) (a company focusing on sales of In Vitro Diagnosis diagnostic reagents) since April 2005, and he has been responsible for the formulating operation plan and investment strategies of the company. Mr. Li has also been a first-tier distributor of Roche In Vitro Diagnostics (羅氏體外外診診斷) in Shanghai, leading the sales team in the area since April 2004. Mr. Li also served as senior management consultant of Jin Hai Holdings (HK) Limited (今海集團(香港)有限公司), a company wholly-owned by Mr. Chen Guobao, our executive Director, between September 2025 and February 2026.

As at the date of this announcement, by virtue of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”), Mr. Li is interested in 40,000,000 shares of the Company.

Save as disclosed above, Mr. Li confirmed that, as at the date of this announcement, he (i) does not hold any other positions with the Company and other members of the Group; (ii) has not held any directorship, and/or any other major appointment and professional qualification in other companies listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and/or overseas in the last three years; (iii) has no relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (iv) has no other major positions in the Group; and (v) does not have any other interest in any shares, underlying shares or debentures of the Company or any of its associated corporation which are required to be disclosed pursuant to Part XV of the SFO.

There is a three-year service contract entered into between the Company and Mr. Li who is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association of the Company.

Mr. Li will receive a fixed director's fee of HK\$200,000 per month. His remuneration is determined by the Board with reference to his roles and responsibilities with the Company and prevailing market conditions.

Save as disclosed above, there is no information in relation to the appointment of the Director that is required to be disclosed according to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Mr. Li to the Board.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

Hong Kong, 3 February 2026

As at the date of this announcement, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Li Bin, Mr. Wang Zhenfei and Mr. Li Yunping; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.